Breaking News Instant updates and real-time market news.

PTCT

PTC Therapeutics

$17.46

0.65 (3.87%)

09:12
09/28/17
09/28
09:12
09/28/17
09:12

PTC Therapeutics trading halted, news pending

The FDA Peripheral & Central Nervous System Drugs Advisory Committee will hold a meeting today to discuss PTC Therapeutics' New Drug Application for ataluren for treatment of patients with dystrophinopathy due to a nonsense mutation in the dystrophin gene.

  • 28

    Sep

  • 24

    Oct

PTCT PTC Therapeutics
$17.46

0.65 (3.87%)

09/27/17
LEER
09/27/17
NO CHANGE
LEER
Outperform
Sarepta doesn't see read through from PTC AdComm, says Leerink
After hosting Sarepta (SRPT) executives, Leerink analyst Joseph Schwartz noted management stated they do not anticipate any read through to Sarepta's exon skipping drugs from the advisory committee meeting to discuss PTC Therapeutics' (PTCT) ataluren as the therapies have different mechanisms and address different disease states. Additionally, the company said Exondys 51's U.S. launch has exceeded expectations, sales outside the U.S. are expected to be slower than U.S. sales, that they see a potential FDA filing for golodirsen in Q1 of 2018 and that they will update guidance in 2018. Schwartz keeps an Outperform rating on Sarepta shares.
09/27/17
SBSH
09/27/17
NO CHANGE
Target $28
SBSH
Buy
Citi sees $22 of upside on positive vote, says buy PTC after selloff
Citi analyst Joel Beatty recommends using yesterday's weakness in shares of PTC Therapeutics as a buying opportunity. The stock closed down 14% to $16.81 after the FDA posted briefing documents ahead of Thursday's panel vote. At current levels, there is almost no value in PTC shares for U.S. Translarna sales, Beatty tells investors in a research note. He sees downside of less than $1 per share if the panel votes against approval, and upside of $22 per share if the panel votes that Translarna is effective. Beatty disagrees that the briefing documents raise concern about management credibility and he believes Translarna will stay on the market in Europe. The analyst keeps a Buy rating on PTC Therapeutics with a $28 price target.
09/26/17
JPMS
09/26/17
NO CHANGE
JPMS
Neutral
PTC briefing documents have 'very negative' tone, says JPMorgan
JPMorgan analyst Anupam Rama says the FDA briefing documents this morning for PTC Therapeutics' panel meeting Thursday have a "very negative" tone. The FDA's conclusion is that the data submitted by PTC is not "persuasive" for approval, Rama tells investors in a research note titled "Multiple Negative Points in Translarna FDA Briefing Docs Make Approval a Low Probability." He also believes management credibility "could be an overhang" based on some of the commentary in the documents. The analyst remains cautious on a positive Translarna panel outcome and approval going into Thursday's panel vote. He would not be surprised to see continued pressure on PTCT shares into the meeting. Rama reiterates a Neutral rating on the shares. PTC in morning trading is down 24%, or $4.72, to $14.79.
09/26/17
JPMS
09/26/17
NO CHANGE
JPMS
JPMorgan sees 'multiple negative points' in PTC briefing documents

TODAY'S FREE FLY STORIES

TGT

Target

$62.92

1.16 (1.88%)

, GOOG

Alphabet

$988.20

3.75 (0.38%)

11:20
10/23/17
10/23
11:20
10/23/17
11:20
Hot Stocks
Target climbs as retailer gears up for crucial holiday season »

EXCLUSIVE BRANDS: After…

TGT

Target

$62.92

1.16 (1.88%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

WMT

Wal-Mart

$88.24

0.8 (0.91%)

AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 08

    Nov

  • 15

    Nov

  • 15

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

  • 18

    Mar

XLF

Financial Select Sector

$26.67

0.025 (0.09%)

11:20
10/23/17
10/23
11:20
10/23/17
11:20
Options
Notable option play in SPDR Financial ETF Monday morning »

Notable option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:20
10/23/17
10/23
11:20
10/23/17
11:20
General news
Treasury announced a $45 B 4-week bill auction for Tuesday »

Treasury announced a $45…

$NSD

NASDAQ Market Internals

11:17
10/23/17
10/23
11:17
10/23/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
10/23/17
10/23
11:16
10/23/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$146.80

-2.81 (-1.88%)

11:15
10/23/17
10/23
11:15
10/23/17
11:15
Options
Palo Alto Networks put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

11:15
10/23/17
10/23
11:15
10/23/17
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

11:15
10/23/17
10/23
11:15
10/23/17
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

SINA

Sina

$110.48

-1.12 (-1.00%)

11:14
10/23/17
10/23
11:14
10/23/17
11:14
Hot Stocks
Aristeia says Glass Lewis endorses nominees for Sina board »

Aristeia Capital, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

JNJ

Johnson & Johnson

$143.95

1.5514 (1.09%)

11:13
10/23/17
10/23
11:13
10/23/17
11:13
Conference/Events
Johnson & Johnson management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

SNY

Sanofi

$49.59

0.075 (0.15%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$28.07

-0.15 (-0.53%)

11:11
10/23/17
10/23
11:11
10/23/17
11:11
Conference/Events
Worldwide Business Research to hold a summit »

BioNetwork Partnering…

SNY

Sanofi

$49.59

0.075 (0.15%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$28.07

-0.15 (-0.53%)

UNH

UnitedHealth

$207.31

-0.18 (-0.09%)

NVS

Novartis

$86.54

0.8 (0.93%)

HZNP

Horizon Pharma

$14.09

-0.05 (-0.35%)

ABBV

AbbVie

$95.55

-0.55 (-0.57%)

BAYRY

Bayer

$34.80

-0.41 (-1.16%)

MRK

Merck

$64.37

0.49 (0.77%)

RDHL

RedHill Biopharma

$9.25

0.47 (5.35%)

NBRV

Nabriva Therapeutics

$6.33

-0.31 (-4.67%)

PFE

Pfizer

$36.68

0.26 (0.71%)

TEVA

Teva

$14.70

-0.2 (-1.34%)

GILD

Gilead

$81.21

-0.38 (-0.47%)

ALXN

Alexion

$139.02

-1.44 (-1.03%)

GSK

GlaxoSmithKline

$40.76

-0.085 (-0.21%)

REGN

Regeneron

$432.98

-7.96 (-1.81%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

LLY

Eli Lilly

$87.85

0.62 (0.71%)

AMGN

Amgen

$182.96

-1.16 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 27

    Oct

  • 27

    Oct

  • 28

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 08

    Nov

  • 09

    Nov

  • 13

    Nov

  • 16

    Nov

  • 16

    Nov

  • 30

    Nov

  • 30

    Nov

  • 02

    Dec

  • 04

    Dec

  • 02

    Feb

  • 03

    Feb

  • 12

    Feb

  • 30

    Apr

  • 17

    May

  • 28

    May

CUB

Cubic

$54.75

1.7 (3.20%)

11:10
10/23/17
10/23
11:10
10/23/17
11:10
Periodicals
MTA ready to roll out new payment system built by Cubic, NY Post reports »

The MTA is ready to roll…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:07
10/23/17
10/23
11:07
10/23/17
11:07
General news
4-Week Bill Announcement Offering Amount data reported »

4-Week Bill Announcement…

NTNX

Nutanix

$26.67

0.33 (1.25%)

11:05
10/23/17
10/23
11:05
10/23/17
11:05
Options
Nutanix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:05
10/23/17
10/23
11:05
10/23/17
11:05
General news
Euro$ interest rate futures are relatively steady »

Euro$ interest rate…

OPGN

OpGen

$0.37

-0.0014 (-0.38%)

11:01
10/23/17
10/23
11:01
10/23/17
11:01
Hot Stocks
OpGen announces award of $860K CDC contract »

OpGen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PETS

PetMed Express

$36.74

0.87 (2.43%)

11:00
10/23/17
10/23
11:00
10/23/17
11:00
Recommendations
PetMed Express analyst commentary  »

PetMed Express target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

EGO

Eldorado Gold

$1.79

-0.38 (-17.51%)

10:57
10/23/17
10/23
10:57
10/23/17
10:57
Downgrade
Eldorado Gold rating change  »

Eldorado Gold downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

TMUS

T-Mobile

$60.46

-1.05 (-1.71%)

, S

Sprint

$6.99

0.055 (0.79%)

10:55
10/23/17
10/23
10:55
10/23/17
10:55
Hot Stocks
T-Mobile adds 1.3M customers as Un-carrier remains mum on potential Sprint deal »

Shares of T-Mobile US…

TMUS

T-Mobile

$60.46

-1.05 (-1.71%)

S

Sprint

$6.99

0.055 (0.79%)

DTEGY

Deutsche Telekom

$18.06

-0.09 (-0.50%)

SFTBF

SoftBank

$88.50

1.25 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 16

    May

HAS

Hasbro

$98.19

1.52 (1.57%)

10:55
10/23/17
10/23
10:55
10/23/17
10:55
Options
Hasbro put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

NWBI

Northwest Bancshares

$17.66

0.08 (0.46%)

10:52
10/23/17
10/23
10:52
10/23/17
10:52
Earnings
Northwest Bancshares reports Q3 EPS 24c, consensus 22c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FAT

Fat Brands

10:52
10/23/17
10/23
10:52
10/23/17
10:52
Syndicate
Fat Brands opens at $12.80, IPO priced at $12 per share »

TriPoint Global acted as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLX

Helix Energy

$6.85

-0.91 (-11.73%)

10:49
10/23/17
10/23
10:49
10/23/17
10:49
Hot Stocks
Helix Energy falls after saying strategic review concluded »

On Helix Energy's Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

DOVA

Dova Pharmaceuticals

$26.73

-0.4 (-1.47%)

10:46
10/23/17
10/23
10:46
10/23/17
10:46
Conference/Events
Dova Pharmaceuticals to hold a pharmaceutical update conference call »

Management, along with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
10/23/17
10/23
10:45
10/23/17
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.